Ranbaxy Laboratories Limited, a pharmaceutical company, produces a range of generic medicines. The company has a presence in 49 countries, manufacturing facilities in 11 countries and serves customers in approximately 125 countries. Products The company manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. Its product basket of approximately 5,000 SKUs available in approximately 125 countries worldwide, encompasses a therapeutic mix covering a majority of the chronic and acute segments. Research & Development The company offers value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes. Novel Drug Delivery Systems (NDDS): The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations. In the oral NDDS space, Ranbaxy has developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. New Drug Discovery Research (NDDR): The company's NDDR program focuses on select therapeutic segments of Infectious diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. The company has 8-10 programs in the area of NDDR. For Arterolane (potential Anti-malarial candidate), the company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials in India. The company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract Infection. Under an alliance with an academic institution in India, various medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The company also has collaborative research projects with other academic institutions in India in the area of Respiratory and Infectious disease. Significant Events In June 2008, Ranbaxy entered into an alliance with Daiichi Sankyo Company Ltd., to create a generic pharmaceutical powerhouse. On September 17, 2009, Ranbaxy Laboratories Ltd. has entered into a strategic in-licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product, Neuronox. Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox. History Ranbaxy Laboratories Limited was founded in 1961.

Taisho Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following divisions: Self-Medication, Prescription Pharmaceutical and Overseas Development. The Self-Medication division deals with the research, development, and production of over-the-counter (OTC) drugs, medical supplies, food for specific health use, and hygiene products. The Prescription Pharmaceutical division handles research and development of new drugs in the fields of central nervous system diseases, metabolic diseases, infectious diseases, and inflammatory diseases. The Overseas Development division markets energy drinks and OTC pharmaceuticals overseas. The company was founded on October 12, 1912 and is headquartered in Tokyo, Japan.

Kyowa Chemical Industry Co. Ltd. engages in the manufacture and sale of magnesium compounds. Its products include magnesium oxide, magnesium hydroxide, synthetic hydrotalcite, carbonate, silicate, acid acceptor, polymer additives & stabilizers, chemical adsorbents, flame retardants, raw materials for metallic salt, food additives and others. The company was founded in September 1952 and is headquartered in Sakaide, Japan.

G��deke GmbH is a German private company located in Dassel that operates as sawmills. The firm was founded in 1981. Torsten G��deke is the current CEO of the firm.

Shenyang Paka Sejing Co., Ltd., established on 1985-10-25, Business scope includes production and pre-sale processing,painting,Environmental friendly,Coating equipment,Plate-mounted heat exchangers and other equipment;Undertake anti-embroidery processing of various metals,Metal Lubrication Processing;Undertake heat treatment;Metal surface treatment agent series products,rolling oil,anti-rust oil(wax),Sealant series products,And the production of chemical products supporting it;Related environmental technical services and maintenance of sewage treatment systems and related industrial services for products.(Involving administrative licensing, with operating permits)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Lion Corp. engages in the manufacture and sale of dental and body care, laundry, household cleaners, pharmaceuticals, and health products. It operates through the following business segments: Consumer Products, Industrial Products, Overseas, and Other. The Consumer Products segment manufactures and sells daily necessities, over-the-counter drugs and function food. These include toothpaste, toothbrush, hand soap, antipyretic analgesic, eye drops, nutritional drink, laundry detergent, softener, and bleach. The Industrial Products segment provides chemical raw materials and business supplies. These include oil and fat activator, conductive carbon, and professional cleaning agent. The Overseas segment handles the operation of overseas subsidiaries that manufactures and sells daily commodities. The Other segment includes construction contracting, real estate management, transportation storage, and staffing. The company was founded by Tomijiro Kobayashi on October 30, 1891 and is headquartered in Tokyo, Japan.

Tokyo Tanabe Co. Ltd., a subsidiary of Cegedim SA, is a Japanese company located in Tokyo. The firm produces and sells medicines.

Chalco Zhengzhou Nonferrous Metal Research Institute Co., Ltd., established on 2015-01-21, The scope of business includes R&D, production and sales of comprehensive utilization of aluminum-magnesium ore products;Aluminum magnesium and its alloy products,Aluminum hydroxide,Aluminum oxide,Various types of alumina,Zirconia and composite powder materials,ceramics,Carbon Materials for Aluminum,Research, development, production and sales of anti-seepage materials and refractory materials;Aluminum and magnesium smelting,Chemical Products(Does not contain flammable, explosive and highly toxic chemicals),Machinery Automation,environmental protection,Research and development, production and sales of testing technology and equipment,Technical Consulting and Technology Transfer;project consultancy,Engineering design and corresponding general contracting of construction projects;Project management and related technical and management services,Energy-saving technical service,Evaluation and corresponding technical services;Realtor;Import and export,Technology Import and Export;Catering and Hotel Services.

Xi'an Hanfeng Pharmaceutical Co., Ltd., established on 2003-03-11, The business scope includes small volume injections(Contains first class psychotropic drugs:Sodium Oxybate Injection),tablet,Capsules,Freeze-dried powder injection(Contains antineoplastic drugs),Production and sales of Class III medical devices;Drug R&D and Technical Services,Goods import and export business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals. Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.” In accordance with this philosophy, as we implement our business activities we strive to realize our vision, which expresses that “Mitsubishi Tanabe Pharma strive to be a global research-driven pharmaceutical company that is trusted by communities.” As a company that is trusted and highly evaluated by patients and health care professionals as well as by society and shareholders, we will implement management with a focus on transparency and fairness while always keeping in mind the starting point of our business activities: “Everything we do is for the patients.”

Aluminum Corp. of China Ltd. engages in the enterprise of non-ferrous metals. It operates through the following business segments: Alumina, Primary Aluminum, Trading, Energy, and Corporate and Other. The Alumina segment includes the mining and purchasing of bauxite and other raw materials, and production and sale of alumina as well as alumina-related products, such as alumina hydrate, alumina-based chemical products and gallium. The Primary Aluminum segment includes the procurement of alumina, other raw materials, supplemental materials and electrical power, the production and sale of primary aluminum and aluminum-related products, such as carbon products, aluminum alloy products, and other electrolytic aluminum products. The Trading segment engages in the trading of alumina, primary aluminum, other non-ferrous metal products, and crude fuels such as coal products, as well as supplemental materials to internal manufacturing plants and external customers. The Energy segment includes coal mining and power generation, including conventional coal-fire power generation and renewable energy generation such as wind power and photovoltaic power. The Corporate and Other segment engages in the corporate and other aluminum-related research, development, and other activities of the group. The company was founded on September 10, 2001 and is headquartered in Beijing, China.

Liaoning Zhengxin Pharmaceutical Research Co., Ltd., established on 2001-07-02, Business scope includes medical technology and biotechnology development,Health food research and development and related technical services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Jiangxi Jiana Energy Technology Co., Ltd., established on 2020-12-28, Business scope includes general items:Electronic special material manufacturing,Sales of electronic special materials,Sales of high-purity elements and compounds,Recycling and Cascade Utilization of Waste Power Batteries for New Energy Vehicles(No Hazardous Waste Operations),New material technology research and development,Import and export,Import and export agency,Technology Import and Export,General Cargo Warehousing Services(Does not contain hazardous chemicals and other items that require approval)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Qingyuan Jiazhi New Materials Research Institute Co., Ltd., established on 2016-11-30, Business scope includes new energy,new material,battery material,Non-ferrous metals(Tungsten free,tin,Antimony, etc. are national monopoly,Exclusive control,monopoly,restricted class,Prohibited metals),Technology research and development in the field of chemical products;Introduction of technology projects,incubation,Pilot test acceleration;Industrial demonstration production;R&D and sales of new technologies and their industrialized supporting equipment;Technology project investment,technology incubation,Industrialization service;Introduction and cultivation of technical talents;Goods import and export trade and related supporting business,Technology import and export trade and related supporting business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Liaoning Yiling Kechuang Biomedical Technology Co., Ltd., established on 2009-01-07, The scope of business includes two types of:6826Physiotherapy and Rehabilitation Equipment,6866Sales of medical polymer materials and products;Biomedical Technology Development,technology transfer;Medical Consulting Services;Diagnostic reagents,Medical Device Technology Development.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.)

Steridose Systems AB, part of Avingtrans Plc, is a company headquartered in Sweden. The firm manufactures pharmaceuticals processing machinery. On March 01, 1996 APV Plc acquired Steridose Systems AB.

Part of Guangdong Dowstone Technology Co., Ltd., Guangdong Jiana Energy Technology Co., Ltd. is a company headquartered in Guangzhou, China. The firm manufactures of cobalt salts and ternary precursors.